Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).

[1]  G. Perilongo,et al.  Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). , 2013, European journal of cancer.

[2]  G. Perilongo,et al.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Christie Powell,et al.  Irinotecan as maintenance therapy in high‐risk hepatoblastoma , 2010, Pediatric blood & cancer.

[4]  B. Morland,et al.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. , 2009, The New England journal of medicine.

[5]  B. Geoerger,et al.  A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). , 2008, European journal of cancer.

[6]  M. Holdsworth,et al.  Risk determinants for catheter‐associated blood stream infections in children and young adults with cancer , 2008, Pediatric blood & cancer.

[7]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Geoerger,et al.  Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  O. Ijichi,et al.  Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single‐agent therapy with irinotecan , 2006, Pediatric transplantation.

[11]  K. Kawa,et al.  IRINOTECAN FOR CHILDREN WITH RELAPSED SOLID TUMORS , 2006, Pediatric hematology and oncology.

[12]  G. Perilongo,et al.  Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group. , 2004, European journal of cancer.

[13]  D. Frappaz,et al.  A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Denise Williams,et al.  Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). , 2003, Medical and pediatric oncology.

[15]  H. Mugishima,et al.  Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma , 2003, Pediatric Surgery International.

[16]  H. Katzenstein,et al.  Novel therapeutic approaches in the treatment of children with hepatoblastoma. , 2002, Journal of pediatric hematology/oncology.

[17]  W. London,et al.  Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. V. von Schweinitz,et al.  Pretreatment prognostic factors and treatment results in children with hepatoblastoma , 2002, Cancer.

[19]  R. McLendon,et al.  Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. , 2002, Neuro-oncology.

[20]  W. Gerald,et al.  Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience , 2002, Journal of pediatric hematology/oncology.

[21]  S. Suita,et al.  Phase I Study of Irinotecan in Pediatric Patients With Malignant Solid Tumors , 2002, Journal of pediatric hematology/oncology.

[22]  E. Eisenhauer,et al.  Application of a new multinomial phase II stopping rule using response and early progression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Perilongo,et al.  Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  D. V. von Schweinitz,et al.  Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: A report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94 , 1999, Klinische Padiatrie.

[26]  P. Houghton,et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Eisenhauer,et al.  Multinomial phase II cancer trials incorporating response and early progression. , 1999, Journal of biopharmaceutical statistics.

[28]  J. O’Leary,et al.  Camptothecins: a review of their development and schedules of administration. , 1998, European journal of cancer.

[29]  J. Hecht.  Gastrointestinal toxicity or irinotecan. , 1998, Oncology.

[30]  M. Bernstein,et al.  Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Sainte-Rose,et al.  Potent therapeutic activity of irinotecan (CPT‐11) and its schedule dependency in medulloblastoma xenografts in nude mice , 1997, International journal of cancer.

[32]  P. Houghton,et al.  Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  B GuzmanBlanco,et al.  Cancer in children , 1953 .

[34]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[35]  G. Perilongo,et al.  Pediatric Liver Tumors , 2011 .

[36]  M. Bernstein,et al.  A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[38]  E. Cvitkovic,et al.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. , 1996, European journal of cancer.

[39]  L. Ferrell,et al.  Pediatric liver tumors. , 1993, Pathology.